Suven Life Sciences has received patent rights from New Zealand for two products The patents are valid through 2029 and 2030, respectively. The drugs granted patents are used in the treatment of cognitive impairment associated with neurodegenerative disorders, such as Alzheimer, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia. The stock on Friday closed with a marginal gain at ₹72.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.